Target site concentrations of ciprofloxacin after single intravenous and oral doses - Wikidata - awgldk - TriplyDB

Target site concentrations of ciprofloxacin after single intravenous and oral doses

Target site concentrations of ciprofloxacin after single intravenous and oral doses

http://www.wikidata.org/entity/Q39671107

about

Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents Ciprofloxacin modulates cytokine/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.Ciprofloxacin as a potential radio-sensitizer to tumor cells and a radio-protectant for normal cells: differential effects on γ-H2AX formation, p53 phosphorylation, Bcl-2 production, and cell death Ciprofloxacin dosage and emergence of resistance in human commensal bacteria Clinical microdialysis in skin and soft tissues: an update.Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents.Relevance of soft-tissue penetration by levofloxacin for target site bacterial killing in patients with sepsis.Transcutaneous sampling of ciprofloxacin and 8-methoxypsoralen by electroporation (ETS technique).Dermal drug levels of antibiotic (cephalexin) determined by electroporation and transcutaneous sampling (ETS) technique.Impact of low-level resistance to fluoroquinolones due to qnrA1 and qnrS1 genes or a gyrA mutation on ciprofloxacin bactericidal activity in a murine model of Escherichia coli urinary tract infection.[18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans.Ciprofloxacin: review on developments in synthetic, analytical, and medicinal aspects.Levofloxacin for the treatment of pyelonephritis.A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.Factors Affecting Penetration of Ciprofloxacin in Lower Extremity Ischemic Tissues.Neutralization of antimicrobial substances in new BacT/Alert FA and FN Plus blood culture bottles.

P2860

Q26827380-5A77DE4A-9F19-47C8-97EE-D296A79DAF42 Q28487821-14A2954A-E056-45E2-80D3-06D16CCCAF63 Q31046210-3841B4A2-2601-4ED3-A979-7529D760CE85 Q34004301-7AA7313A-3BA1-49CD-8A63-D329BB4E0D05 Q34104262-A498E88F-0E82-4D0A-8242-EDA1B8130B46 Q34752069-3F605FDC-3F20-47E4-953E-A4423925D2B2 Q36162355-DA399EFE-C10C-46A2-B378-93C6F2622232 Q36880013-8D5E4EE0-247A-40A7-809A-D01CE2EB29F6 Q37183990-245E4B2A-BD71-480C-88D1-105F5210CF02 Q37335289-9B9B85B8-DAB7-46DF-AB5F-040DAF6FC195 Q37392904-FBAB041B-D579-4C86-B498-2DDCACA443B2 Q37568411-4E8C9C4D-E65F-4CE0-B397-0E70C502F389 Q37710505-9BDE9121-8FD4-4E7C-B469-60AB393BDD78 Q38101380-2CCAC3FB-1406-41F9-B059-21E3D8858BBC Q38223948-D78408C1-9387-4C8C-8249-9FA8665A6534 Q38582536-BA40314B-60F6-430A-93EC-6570210C6B9A Q38949043-A7F83319-A984-47A5-A69F-C069749EC5F6 Q40164488-6BF59D7A-80D6-4C77-8777-FE9521CF7532 Q40519608-0F2FD0CC-1629-404F-8D7E-DC04DD59674C

P2860

Target site concentrations of ciprofloxacin after single intravenous and oral doses

http://www.wikidata.org/entity/Q39671107

description

2002 nî lūn-bûn

@nan

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

2002年论文

@zh

2002年论文

@zh-cn

name

Target site concentrations of ciprofloxacin after single intravenous and oral doses

@en

Target site concentrations of ciprofloxacin after single intravenous and oral doses.

@nl

type

label

Target site concentrations of ciprofloxacin after single intravenous and oral doses

@en

Target site concentrations of ciprofloxacin after single intravenous and oral doses.

@nl

prefLabel

Target site concentrations of ciprofloxacin after single intravenous and oral doses

@en

Target site concentrations of ciprofloxacin after single intravenous and oral doses.

@nl

P1433

Q39671107-9F89F22D-59D4-46C1-9B9E-23BD37971539

P1476

Q39671107-5B6C6224-2513-4380-98E4-8F4CE5714F5E

P2093

Q39671107-0EBC163F-CBDD-44F7-982C-8EFCF6F7C381

Q39671107-1961F19D-B841-4ABC-AD37-4CA1CFE572EB

Q39671107-1E836CF5-A348-416F-8387-917B349BDD07

Q39671107-40B3A2B2-AE28-449B-818E-4B6465921176

Q39671107-9C90AE3F-E3FE-45D8-A584-9D1441B50484

Q39671107-BFDAB78E-4D59-407A-A7BC-CD78F0B8ADBF

Q39671107-CCD85029-173E-4C05-9F45-68A619B35769

P2860

Q39671107-269EF8D8-C334-4BEF-8437-B964D3C5800E

Q39671107-30B093A0-251C-4A54-AC66-155EAE3DDC10

Q39671107-36C9DD06-0AD6-4200-A0C2-2A374CBC2B3E

Q39671107-3DB30E3D-5FA0-4E10-A8E3-DC3DB4352EDD

Q39671107-4C722D40-2F7F-4B32-B73A-D60887B99124

Q39671107-5F663104-BFA8-4CA6-97B4-7655C797A65D

Q39671107-821D84F1-B30E-437A-9DB2-74FA35C1CFC8

Q39671107-85E7D495-F8DC-43D8-AAF9-F21652505AFD

Q39671107-8BA6D02D-993A-46FA-88BB-A342948E8B2C

Q39671107-90A44E4E-0912-4785-A6E1-EC61E5025D53

P304

Q39671107-C118790D-0A63-4EDB-9B3F-EBC929BDFEE5

P31

Q39671107-770E41DE-A2AA-4EE4-8A17-8057F2930F1B

P356

Q39671107-F75A21FF-F2AF-4468-8397-D503C938EB6C

P407

Q39671107-9453A560-81A7-4B1E-B0FB-E1F2DBFD5A77

P433

Q39671107-4548FBD5-F9C0-486D-906F-5D519CA62C5F

P478

Q39671107-34079EC2-9824-4FE8-B41C-298AB0BCF151

P50

Q39671107-AEDCF51A-8400-41F7-B946-0F443F6280E9

Q39671107-F762C365-91BD-41CB-94B1-02F60B4B600B

P577

Q39671107-551519FA-639E-4486-8B5D-B3AA4652286A

P5875

Q39671107-E20E5E7C-0479-4CF6-8CE0-A0F929C8A37A

P698

Q39671107-2A6B653C-7D9F-45AF-9CC2-DDE7680ACA31

P932

Q39671107-360F5E9B-44A4-4A3D-B990-3ED77B2D20F8

P356

AAC.46.12.3724-3730.2002

P1433

Antimicrobial Agents and Chemotherapy

P1476

Target site concentrations of ciprofloxacin after single intravenous and oral doses

@en

P2093

Claudia Schrolnberger

http://www.w3.org/2001/XMLSchema#string

Hans Georg Eichler

http://www.w3.org/2001/XMLSchema#string

Heino Stabeta

http://www.w3.org/2001/XMLSchema#string

Jan-Georg Möller

http://www.w3.org/2001/XMLSchema#string

Markus Müller

http://www.w3.org/2001/XMLSchema#string

Martin Brunner

http://www.w3.org/2001/XMLSchema#string

Ursula Hollenstein

http://www.w3.org/2001/XMLSchema#string

P2860

The global epidemiology of resistance to ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective.

Pharmacoeconomics of antimicrobial therapy.

Penetration of ciprofloxacin into the interstitial space of inflamed foot lesions in non-insulin-dependent diabetes mellitus patients

Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans

Capillary electrophoresis with laser-induced fluorescence detection, an adequate alternative to high-performance liquid chromatography, for the determination of ciprofloxacin and its metabolite desethyleneciprofloxacin in human plasma.

Intracellular distribution and activity of antibiotics.

Distribution and antimicrobial activity of ciprofloxacin in human soft tissues.

The selection of appropriate dosages for intravenous ciprofloxacin.

Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.

Cellular uptake, localization and activity of fluoroquinolones in uninfected and infected macrophages.

P304

3724-3730

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.46.12.3724-3730.2002

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Markus Alexander Zeitlinger

P577

2002-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11031546

http://www.w3.org/2001/XMLSchema#string

P698

12435668

http://www.w3.org/2001/XMLSchema#string

P932

132760

http://www.w3.org/2001/XMLSchema#string